Two Epidermolysis Bullosa Nonprofits United to Make the Largest Global Organization for EB

EB Research Partnership (EBRP) is based out of New York, United States. EB Research Foundation (EBRF) is an organization based out of Australia with the same goals. The two organizations  have…

Continue Reading Two Epidermolysis Bullosa Nonprofits United to Make the Largest Global Organization for EB
Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval
source: pixabay.com

Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval

According to a story from prnewswire.com, the biopharmaceutical company InMed Pharmaceuticals, Inc. has recently announced that that company's Clinical Trial Application has been approved in the Netherlands. This approval will…

Continue Reading Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval
With Clinical Hold Lifted, Abeona Moves Forward with Recessive Dystrophic Epidermolysis Bullosa Trial
source: pixabay.com

With Clinical Hold Lifted, Abeona Moves Forward with Recessive Dystrophic Epidermolysis Bullosa Trial

According to a story from Benzinga, the drug company Abeona Therapeutics, Inc. has recently announced plans to move forward with its phase 3 clinical trial following the lifting of the…

Continue Reading With Clinical Hold Lifted, Abeona Moves Forward with Recessive Dystrophic Epidermolysis Bullosa Trial
Abeona Faces Clinical Hold from the FDA Ahead of Epidermolysis Bullosa Trial
Free-Photos / Pixabay

Abeona Faces Clinical Hold from the FDA Ahead of Epidermolysis Bullosa Trial

According to a story from globenewswire.com, the gene and cell therapy company Abeona Therapeutics Inc. recently announced that has received a letter from the US Food and Drug Administration (FDA)…

Continue Reading Abeona Faces Clinical Hold from the FDA Ahead of Epidermolysis Bullosa Trial

Results From First Patient Treated in Epidermolysis Bullosa Phase 2 Trial are Extremely Promising

Epidermolysis Bullosa Epidermolysis bullosa (EB) is a rare condition affecting approximately 500,000 individuals globally. Patients in the United States and Europe account for 50,000 of these individuals. The hereditary condition is…

Continue Reading Results From First Patient Treated in Epidermolysis Bullosa Phase 2 Trial are Extremely Promising

Companies Announce Collaboration to Develop Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

According to a story from globenewswire.com, the gene therapy company Fibrocell Science, Inc. and the biopharmaceutical company Castle Creek Pharmaceuticals have recently announced a collaboration between the two companies. The…

Continue Reading Companies Announce Collaboration to Develop Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Phase 2 Trial Results for Epidermolysis Bullosa Coming Second Quarter of 2019

Epidermolysis Bullosa Epidermolysis Bullosa (EB) refers to a group of rare conditions which are characterized by fragile skin. Basically, the disease is caused by separation between the layers of the skin.…

Continue Reading Phase 2 Trial Results for Epidermolysis Bullosa Coming Second Quarter of 2019
Phase 1 Gene Transfer Trial for Recessive Dystrophic Epidermolysis Bullosa is Recruiting Patients
PixLoger / Pixabay

Phase 1 Gene Transfer Trial for Recessive Dystrophic Epidermolysis Bullosa is Recruiting Patients

According to a story from Debra of America, a new Phase 1 clinical trial being operated by Stanford University is currently recruiting participants. This trial will be a test of…

Continue Reading Phase 1 Gene Transfer Trial for Recessive Dystrophic Epidermolysis Bullosa is Recruiting Patients
Drug Developer Receives $900,000 for the Development of a Gene Therapy for Epidermolysis Bullosa
ColiN00B / Pixabay

Drug Developer Receives $900,000 for the Development of a Gene Therapy for Epidermolysis Bullosa

According to a story from pm360online.com, the gene therapy company Fibrocell Science, Inc., recently received an investment of $900,000 from the Epidermolysis Bullosa Medical Research Foundation (EBMRF) and the EB…

Continue Reading Drug Developer Receives $900,000 for the Development of a Gene Therapy for Epidermolysis Bullosa
This Company Will Work With Nonprofit Organizations to Develop New Treatment for Epidermolysis Bullosa
DarkoStojanovic / Pixabay

This Company Will Work With Nonprofit Organizations to Develop New Treatment for Epidermolysis Bullosa

According to a story from PR Newswire, the biopharmaceutical company Constant Pharmaceuticals recently announced that it plans to develop its experimental compound TXA127 as a therapy for epidermolysis bullosa (EB).…

Continue Reading This Company Will Work With Nonprofit Organizations to Develop New Treatment for Epidermolysis Bullosa
Phase 2 Trial for an Experimental Epidermolysis Bullosa Treatment Begins Enrollment
chezbeate / Pixabay

Phase 2 Trial for an Experimental Epidermolysis Bullosa Treatment Begins Enrollment

According to a story from epidermolysisbullosanews.com, the biotechnology company TWi Biotechnology, Inc., recently announced that is has begun enrollment for its Phase 2 trial. This trial will test the company's…

Continue Reading Phase 2 Trial for an Experimental Epidermolysis Bullosa Treatment Begins Enrollment
Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa
LaCasadeGoethe / Pixabay

Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa

Two companies, GtreeBNT and YuYang DNU, will collaborate in a joint venture to develop the investigational drug RGN-137 for the treatment of epidermolysis bullosa. For more details, you can read…

Continue Reading Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa
A Drug Being Developed to Treat Epidermolysis Bullosa Has Been Granted Orphan Drug Status
Source: Pixabay

A Drug Being Developed to Treat Epidermolysis Bullosa Has Been Granted Orphan Drug Status

The Boston-based biopharmaceutical company Berg LLC has announced that their experimental drug candidate BPM 31510 (ubidecarenone) has been awarded Orphan Drug designation by the US Food and Drug Administration (FDA)…

Continue Reading A Drug Being Developed to Treat Epidermolysis Bullosa Has Been Granted Orphan Drug Status